PubRank

Andrew Wei

Author PubWeight™ 35.75‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005 13.59
2 Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005 8.95
3 Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 2012 2.44
4 The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells. Haematologica 2006 1.05
5 Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse. Leuk Lymphoma 2012 0.92
6 Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer 2013 0.90
7 Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma. Haematologica 2005 0.88
8 Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL. J Med Chem 2013 0.86
9 Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone. Leuk Lymphoma 2007 0.85
10 Fli-1 overexpression in hematopoietic progenitors deregulates T cell development and induces pre-T cell lymphoblastic leukaemia/lymphoma. PLoS One 2013 0.84
11 Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients. Clin Cancer Res 2013 0.83
12 Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. Am J Hematol 2014 0.78
13 Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome. Br J Clin Pharmacol 2013 0.77
14 Rapid detection of FLT3 exon 20 tyrosine kinase domain mutations in patients with acute myeloid leukemia by high-resolution melting analysis. Leuk Lymphoma 2012 0.77
15 Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics. Cancer Cell 2016 0.77
16 Optimal approach for high-risk acute promyelocytic leukemia. Curr Opin Hematol 2014 0.76
17 Salvaging AML with CLAG: novel option, or more of the same? Leuk Res 2010 0.75
18 Revisiting late relapses in acute myeloid leukemia. Leuk Lymphoma 2010 0.75
19 The Patients' Perspective: Hematological Cancer Patients' Experiences of Adverse Events as Part of Care. J Patient Saf 2017 0.75
20 Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy. Br J Haematol 2012 0.75
21 Improving the Transition to Palliative Care for Patients With Acute Leukemia: A Coordinated Care Approach. Cancer Nurs 2016 0.75
22 Cardiac Imaging in FIP1L1-PDGFRA. J Am Coll Cardiol 2013 0.75
23 Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Leuk Lymphoma 2009 0.75
24 Improving the transition of highly complex patients into the community: impact of a pharmacist in an allogeneic stem cell transplant (SCT) outpatient clinic. Support Care Cancer 2013 0.75